Nanobiotix S.A. (NBTX) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles.
Analysis Summary
Nanobiotix S.A. reported revenue of $29.6M in the most recent fiscal year, growing at a 5-year CAGR of 66.4%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -36.5%, net margin -80.8%.
At the current price of $34.40, NBTX has negative trailing earnings (P/E not meaningful) and an ROE of 31.23%. Market capitalisation stands at $1.7B.
Balance sheet quality for NBTX: current ratio of 1.1, net debt of $42.6M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $34.40 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | FR |
Valuation Ratios
| Price / Book | -15.69 |
| EV / EBITDA | -140.35 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 31.23% |
| Return on Invested Capital | -74.29% |
| Return on Assets | -35.36% |
| Gross Margin | 100.00% |
| Operating Margin | -36.49% |
| Net Margin | -80.83% |
Financial Health
| Debt / Equity | -1.13 |
| Current Ratio | 1.09 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 3.22 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NBTX | Nanobiotix S.A. | $1.7B | 31.2% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | -16.26% |
| 3 months | -5.16% |
| Year-to-date | +48.79% |
| 1 year | +237.25% |
| 3 years | +271.29% |
52-Week Range
| 52-week High | $57.14 |
| 52-week Low | $9.72 |
| Avg Volume (90d) | 118K |
Related companies: ABUS · EYPT · GHRS · KURA · LENZ · PROK · RZLT
Explore sector: Healthcare · Biotechnology
More sections of NBTX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks